TABLE 1.
List of apoB-100-derived tryptic peptides carrying modifications generated by reagent HOCl
| Peptide | Error (ppm) | Peptide Score | % SPI | Z | Sequence with Fragmentation | Modified Amino Acid |
| 1–14 | 1.9 | 17.8 | 91 | 2 | (-)E E/E m/L/E/N/V|S/L/V|C/P K(D) | O-Met4 |
| 91–101 | 0.5 | 12.9 | 71 | 2 | (K)N S|E|E|F/A/A/A/m/S/R(Y) | O-Met99 |
| 203–220 | 3.3 | 17.8 | 92 | 2 | (K)G m/T R\P L\S T L|I|S|S|S Q|S|C|Q\Y(T) | O-Met204 |
| 249–260 | 2.1 | 18.0 | 85 | 2 | (K)Y G/m|V|A|Q|V|T/Q/T L/K(L) | O-Met251 |
| 279–287 | 2.0 | 13.6 | 93 | 2 | (K)m/G|L|A/F/E/S T/K(S) | O-Met279 |
| 401–407 | 3.0 | 10.2 | 79 | 2 | (R)E I|F/N/m/A/R(D) | O-Met405 |
| 464–480 | 3.0 | 15.2 | 76 | 2 | (R)V/I/G/N m|G Q/T m E Q/L/T|P E/L/K(S) | O-Met468, 472 |
| 486–498 | 3.5 | 11.6 | 74 | 3 | (K)C/V|Q/S T K/P S L m I Q/K(A) | O-Met495 |
| 532–540 | 1.3 | 15.5 | 85 | 2 | (R)L/A|A|Y|L/m L/m/R(S) | O-Met537, 539 |
| 550–563 | 1.9 | 17.5 | 82 | 3 | (K)I V|Q\I|L/P\w/E/Q/N E Q V/K(N) | OxTrp556 |
| 550–563 | 1.2 | 14.0 | 84 | 2 | (K)I V|Q|I|L|P w E Q N E Q V/K(N) | di-OxTrp556 |
| 594–604 | 2.3 | 15.7 | 92 | 2 | (K)E S/Q|L|P/T V/m/D/F R(K) | O-Met601 |
| 691–705 | 0.5 | 14.9 | 80 | 2 | (K)A L/Y|w|V|n/G Q/V|P D G V|S K(V) | OxTrp694 |
| 691–705 | 1.1 | 16.3 | 92 | 2 | (K)A L|Y|w|V|n G Q/V|P D G V/S K(V) | di-OxTrp694 |
| 706–715 | 1.9 | 8.3 | 71 | 3 | (K)V/L|V/D H F G y T/K(D) | Cl-Tyr713 |
| 771–777 | 3.0 | 11.5 | 86 | 2 | (K)L/L|L/m/G A/R(T) | O-Met774 |
| 778–791 | 2.7 | 13.1 | 86 | 2 | (R)T L|Q|G|I|P Q m I G E V I/R(K) | O-Met785 |
| 837–846 | 1.4 | 10.1 | 89 | 2 | (K)L E\V\A N m\Q\A|E|L(V) | O-Met842 |
| 870–891 | 3.9 | 19.0 | 83 | 3 | (R)S G/V|Q|m/N/T/N/F F/H E S G L E A H V/A/L/K(A) | O-Met874 |
| 1,029–1,051 | 3.4 | 17.9 | 97 | 2 | (R)q S m T\L\S\S E\V|Q/I|P D F/D V/D L/G T I/L/R(V) | O-Met1031 |
| 1,119–1,132 | 0.6 | 20.4 | 70 | 2 | (K)L L|L|Q/m/D S/S/A T A/Y/G S/T V/S/K(R) | O-Met1123 |
| 1,162–1,175 | 2.2 | 15.7 | 93 | 2 | (K)m T|S/N/F|P V/D/L/S D/Y/P K(S) | O-Met1162 |
| 1,176–1,183 | 1.2 | 11.3 | 62 | 2 | (K)S/L/H|m/Y/A N/R(L) | O-Met1179 |
| 1,203–1,213 | 1.1 | 18.2 | 87 | 2 | (K)L I|V|A|m/S/S/W/L/Q/K(A) | O-Met1207 |
| 1,203–1,213 | 2.3 | 12.0 | 81 | 2 | (K)L/I|V|A/m S S w/L Q/K(A) | O-Met1207 OxTrp1210 |
| 1,676–1,697 | 0.4 | 23.7 | 94 | 2 | (K)A A L T/E\L|S|L/G|S/A/Y/Q/A m/I/L/G/V/D/S K(N) | O-Met1690 |
| 1,871–1,876 | 1.1 | 8.2 | 91 | 1 | (R)S V|m|A|P\F(T) | O-Met1873 |
| 1,890–1,901 | 3.8 | 14.1 | 91 | 2 | (K)L A|L|W/G E H T G Q|L\y(S) | Cl-Tyr1901 |
| 1,986–2,016 | 3.2 | 18.0 | 82 | 3 | (R)T L A D/L T L L\D S P I K V|P L\L\L|S/E|P I/N I|I/D A L/E/m R(D) | O-Met2015 |
| 2,214–2,228 | 0.3 | 11.7 | 63 | 2 | (K)S G S S T/A|S/w/I|Q/N V/D|T K(Y) | OxTrp2221 |
| 2,321–2,333 | 0.8 | 19.4 | 81 | 2 | (R)Y E|V|D Q/Q/I|Q/V|L/m/D K(L) | O-Met2331 |
| 2,462–2,470 | 0.8 | 10.2 | 74 | 2 | (K)I/T|L/I I N w L Q(E) | OxTrp2468 |
| 2,565–2,582 | 2.2 | 22.7 | 93 | 2 | (K)T I|L/G T/m|P A/F/E/V/S L/Q/A/L/Q K(A) | O-Met2570 |
| 2,979–2,993 | 4.6 | 12.9 | 73 | 3 | (K)G/m|A|L|F G E/G K/A E/F T G R(H) | O-Met2980 |
| 3,122–3,128 | 1.5 | 6.6 | 64 | 2 | (K)D F|S/L w/E K(T) | OxTrp3126 |
| 3,237–3,249 | 2.2 | 21.6 | 90 | 2 | (F)T/I|E|m/S/A/F/G Y/V|F/P K(A) | O-Met3240 |
| 3,250–3,264 | 2.7 | 21.1 | 93 | 2 | (K)A V|S|m|P/S/F/S I/L|G/S D/V R(V) | O-Met3253 |
| 3,423–3,434 | 2.6 | 12.1 | 80 | 3 | (K)S K P T\V|S|S/S m E F/K(Y) | O-Met3431 |
| 3,926–3,946 | 1.6 | 15.1 | 75 | 3 | (R)D F|S|A/E|Y/E E/D G K Y E/G L/Q E w E G K(A) | OxTrp3943 |
| 4,080–4,094 | 0.0 | 16.0 | 72 | 2 | (R)N L/Q|N N|A/E/w/V/Y/Q/G A/I/R(Q) | OxTrp4087 |
| 4,080–4,094 | 2.1 | 19.4 | 88 | 2 | (R)N/L|Q|N N\A|E\w/V|Y/Q/G A/I/R(Q) | di-OxTrp4087 |
| 4,187–4,195 | 2.9 | 14.9 | 89 | 2 | (R)E E|L/C/T/m/F/I/R(E) | O-Met4192 |
| 4,235–4,243 | −0.1 | 11.2 | 80 | 2 | (K)L I|D|V|I/S/m/Y R(E) | O-Met4241 |
LDL was modified by HOCl added as a reactant (50 or 100 µM) (oxidant/LDL molar ratio = 25:1 and 50:1). ApoB-100 mapping was carried out by RRLC-MS/MS. Each modified peptide is characterized by its peptide score, % SPI, mass error, fragmentation, and position(s) of modified residue(s).